Abstract:Background: Alzheimer's disease (AD), an age-associated neurodegenerative disorder, currently lacks effective clinical therapeutics. Traditional Chinese Medicine (TCM) holds promising potential in AD treatment, exemplified by Danggui Shaoyao San (DSS), a TCM formulation. The precise therapeutic mechanisms of DSS in AD remain to be fully elucidated. This study aims to uncover the therapeutic efficacy and underlying mechanisms of DSS in AD, employing an integrative approach encompassing gut microbiota and metabolomic analyses. Methods: Thirty Sprague-Dawley (SD) rats were allocated into three groups: Blank Control (Con), AD Model (M), and Danggui Shaoyao San (DSS). AD models were established via bilateral intracerebroventricular injections of streptozotocin (STZ). DSS was orally administered at 24 g·kg −1 ·d −1 (weight of raw herbal materials) for 14 days. Cognitive functions were evaluated using the Morris Water Maze (MWM) test. Pathological alterations were assessed through hematoxylin and eosin (HE) staining. Bloodstream metabolites were characterized, gut microbiota profiled through 16S rDNA sequencing, and cortical metabolomics analyzed. Hippocampal proinflammatory cytokines (IL-1β, IL-6, TNF-α) were quantified using RT-qPCR, and oxidative stress markers (SOD, CAT, GSH-PX, MDA) in brain tissues were measured with biochemical assays. Results: DSS identified a total of 1,625 bloodstream metabolites, predominantly Benzene derivatives, Carboxylic acids, and Fatty Acyls. DSS significantly improved learning and spatial memory in AD rats and ameliorated cerebral tissue pathology. The formulation enriched the probiotic Ligilactobacillus, modulating metabolites like Ophthalmic acid (OA), Phosphocreatine (PCr), Azacridone A, Inosine, and NAD. DSS regulated Purine and Nicotinate-nicotinamide metabolism, restoring balance in the Candidatus Saccharibacteria-OA interplay and stabilizing gut microbiota-metabolite homeostasis. Additionally, DSS reduced hippocampal IL-1β, IL-6, TNF-α expression, attenuating the inflammatory state. It elevated antioxidative enzymes (SOD, CAT, GSH-PX) while reducing MDA levels, indicating diminished oxidative stress in AD rat brains. Conclusion: DSS addresses AD pathology through multifaceted mechanisms, encompassing gut microbiome regulation, specific metabolite modulation, and the mitigation of inflammation and oxidative stress within the brain. This holistic intervention through the Microbial-Gut-Brain Axis (MGBA) underscores DSS's potential as an integrative therapeutic agent in combatting AD.

Pseudostellaria heterophylla polysaccharide mitigates Alzheimer's-like pathology via regulating the microbiota-gut-brain axis in 5 × FAD mice

Stigmasterol Attenuates Inflammatory Response of Microglia Via NF-κB and NLRP3 Signaling by AMPK Activation.

Whey Protein Hydrolysate Intervention Ameliorates Memory Deficits in APP/PS1 Mice: Unveiling Gut Microbe–short‐chain Fatty Acid–brain Axis

Mannan Oligosaccharide Attenuates Cognitive and Behavioral Disorders in the 5xfad Alzheimer's Disease Mouse Model Via Regulating the Gut Microbiota-Brain Axis

Anti-Alzheimers molecular mechanism of icariin: Insights from gut microbiota and metabolome combined network pharmacology

Β‐glucan Attenuates Cognitive Impairment of APP/PS1 Mice Via Regulating Intestinal Flora and Its Metabolites

Polysaccharide from Polygala tenuifolia alleviates cognitive decline in Alzheimer's disease mice by alleviating Aβ damage and targeting the ERK pathway

Plasmon-activated water as a therapeutic strategy in Alzheimer's disease by altering gut microbiota

Fructooligosaccharides Ameliorating Cognitive Deficits and Neurodegeneration in APP/PS1 Transgenic Mice Through Modulating Gut Microbiota.

Structural Characterization of Polysaccharide Purified from Amanita Caesarea and Its Pharmacological Basis for Application in Alzheimer's Disease: Endoplasmic Reticulum Stress

P-coumaric acid ameliorates Aβ 25–35 -induced brain damage in mice by modulating gut microbiota and serum metabolites

A monomeric polysaccharide from Polygonatum sibiricum improves cognitive functions in a model of Alzheimer's disease by reshaping the gut microbiota

Poria cocos could ameliorate cognitive dysfunction in APP / PS1 mice by restoring imbalance of Aβ production and clearance and gut microbiota dysbiosis

Chronic administration of prebiotics and probiotics ameliorates pathophysiological hallmarks of Alzheimer's disease in a APP/PS1 transgenic mouse model

Sodium oligomannate therapeutically remodels gut microbiota and suppresses gut bacterial amino acids-shaped neuroinflammation to inhibit Alzheimer’s disease progression

Structural characterization of Hericium coralloides polysaccharide and its neuroprotective function in Alzheimer's disease

Danggui Shaoyao San: comprehensive modulation of the microbiota-gut-brain axis for attenuating Alzheimer's disease-related pathology

A new intestinal supplement 'Synbiotics' therapeutically regulates gut microbiota and activates PPARs pathway to inhibit Alzheimer's disease progression in mouse models

Prebiotics modulate the microbiota–gut–brain axis and ameliorate cognitive impairment in APP/PS1 mice

Danggui Shaoyao San: Comprehensive Modulation of the Microbiota-Gut-brain Axis for Attenuating Alzheimer’s Disease-Related Pathology

In-depth Investigation of the Mechanisms of Schisandra Chinensis Polysaccharide Mitigating Alzheimer's Disease Rat Via Gut Microbiota and Feces Metabolomics.